Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATHA Athira Pharma Inc
- Stocks
- Healthcare
- NASDAQ: ATHA
Price (delayed)
$0.272
Market cap
$10.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
-$15.32M
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive
Highlights
ATHA's quick ratio has soared by 72% from the previous quarter and by 42% YoY
The EPS is up by 32% YoY and by 18% QoQ
ATHA's equity has plunged by 65% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of ATHA
Market
Valuations
Earnings
Shares outstanding
39.04M
Market cap
$10.62M
Enterprise value
-$15.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$82.75M
Net income
-$79.75M
EBIT
-$79.75M
EBITDA
-$78.53M
Free cash flow
-$86.06M
Per share
Balance sheet
Liquidity
EPS
-$2.07
EPS diluted
-$2.07
Free cash flow per share
-$2.2
Book value per share
$0.96
Revenue per share
$0
TBVPS
$1.11
Total assets
$43.51M
Total liabilities
$6.18M
Debt
$1.12M
Equity
$37.33M
Working capital
$34.36M
Debt to equity
0.03
Current ratio
7.26
Quick ratio
6.79
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-106.4%
Return on equity
-143%
Return on invested capital
N/A
Return on capital employed
-209.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATHA stock price
How has the Athira Pharma stock price performed over time
Intraday
-2.54%
1 week
6.96%
1 month
18.78%
1 year
-89.96%
YTD
-53.64%
QTD
-4.53%
Financial performance
How have Athira Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.75M
Net income
-$79.75M
Gross margin
N/A
Net margin
N/A
ATHA's operating income is up by 33% YoY and by 18% from the previous quarter
ATHA's net income is up by 31% year-on-year and by 18% since the previous quarter
Price vs fundamentals
How does ATHA's price correlate with its fundamentals
Growth
What is Athira Pharma's growth rate over time
Valuation
What is Athira Pharma stock price valuation
P/E
N/A
P/B
0.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 32% YoY and by 18% QoQ
ATHA's P/B is 75% below its 5-year quarterly average of 1.1 and 53% below its last 4 quarters average of 0.6
ATHA's equity has plunged by 65% YoY and by 17% from the previous quarter
Efficiency
How efficient is Athira Pharma business performance
ATHA's return on equity has dropped by 77% year-on-year and by 8% since the previous quarter
Athira Pharma's ROA has plunged by 57% YoY and by 7% from the previous quarter
Dividends
What is ATHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATHA.
Financial health
How did Athira Pharma financials performed over time
ATHA's total liabilities has dropped by 77% year-on-year and by 56% since the previous quarter
Athira Pharma's current ratio has soared by 74% from the previous quarter and by 44% YoY
The company's debt is 97% lower than its equity
The company's debt to equity has surged by 200% YoY
ATHA's equity has plunged by 65% YoY and by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.